ObsEva announces Ed Mathers to its Board along with closing $60m Series B Equity Financing
– SWITZERLAND, Geneva – ObsEva, a Swiss biopharmaceutical company developing a novel generation of drugs addressing serious conditions compromising pregnancy from conception to birth, today announced the closing of a CHF 60 (USD 60) million Series B preferred equity financing.…